Table 1 SLR inclusion criteria
Criteria | Include | Exclude |
|---|---|---|
Population | • Patients with gMG (including subtypes such as AChR + , MuSK + , seronegative, LPR4 + , early-onset, late-onset, refractory, or crisis MG as well as biological sex) • Mixed MG populations that exceed the prespecified proportion of gMG patients (> 80%) | • Patients with oMG • Mixed MG populations that are ≤ 80% gMG patients |
Intervention and comparator(s) | No restriction | NA |
Outcomes | • Patient burden, measured using: o Generic PROMs, e.g., EQ-5D (EQ-5D-3L, EQ-5D-5L), SF-36, WPAI, fatigue, treatment satisfaction, HADS, SF8, STAI, PTSD checklist, PHQ-9, FACIT fatigue scale, PGIS, PGIC o Disease-specific PROMs, e.g. MG-ADL, MG-QoL15 o Disability related to uncontrolled symptoms o Treatment-related comorbidities o Factors associated with increased impact (e.g. gender, age, income) • Patient experience/voice o Psychological impact o Fear o Lifestyle adaptations – home, work/occupation, hobbies, travels o Impact on family planning • Economic burden/resource use o Presenteeism/absenteeism o Out-of-pocket treatment costs o Hospital/ICU length of stay o Number of outpatient visits o Wider societal impact o Access to specialist care o Impact on family planning | NA |
Study design | • Observational studies to include: o Epidemiological studies o Cohorts o Cross sectional studies o Patient surveys o Registries o Case series • Government/regulatory reports • Reports from other companies | • Studies conducted in a controlled, clinical setting • Single case studies/reports • PROM validation studies • Narrative/systematic reviewsa |
Geography | EMEA (data for mixed geographic region were of interest if at least one region of interest were included) | NA |
Date of publication | No restriction for journal articles | Pre-2019 conference abstracts |
Language of publication | English language publications or non-English language publications with an English abstract | NA |